Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide red - risperidone tablet is indicated for the treatment of schizophrenia and related psychoses. risperidone tablet is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperidone tablet is indicated for the treatment of behavioural disturbances in dementia. risperidone tablet is indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. risperidone tablet is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide yellow - risperidone tablet is indicated for the treatment of schizophrenia and related psychoses. risperidone tablet is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperidone tablet is indicated for the treatment of behavioural disturbances in dementia. risperidone tablet is indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. risperidone tablet is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; sunset yellow fcf aluminium lake - risperidone tablet is indicated for the treatment of schizophrenia and related psychoses. risperidone tablet is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperidone tablet is indicated for the treatment of behavioural disturbances in dementia. risperidone tablet is indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. risperidone tablet is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol - risperidone tablet is indicated for the treatment of schizophrenia and related psychoses. risperidone tablet is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperidone tablet is indicated for the treatment of behavioural disturbances in dementia. risperidone tablet is indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. risperidone tablet is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - midazolam 1 mg/ml (present as 1.1111mg/ml midazolam hydrochloride);   - solution for injection - 1 mg/ml - active: midazolam 1 mg/ml (present as 1.1111mg/ml midazolam hydrochloride)   excipient: hydrochloric acid sodium chloride sodium hydroxide as 1n solution, for ph adjustment, ph 3.3±0.1 water for injection - hypnovel is indicated for adults · premedication before induction of anaesthesia · conscious sedation before diagnostic or surgical interventions carried out under local anaesthesia · long-term sedation in intensive care units · induction and maintenance of anaesthesia. as an induction agent in inhalation anaesthesia or a sleep-inducing component in combined anaesthesia, including total intravenous anaesthesia. children · premedication before induction of anaesthesia · conscious sedation before diagnosticc or surgical interventions carried out under local anaesthesia · ataralgesia in combination with ketamine · ataralgesia in combination with ketamine in children (i.m. administration).

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - midazolam 5 mg/ml (present as midazolam hydrochloride 5.5556mg/ml);   - solution for injection - 5 mg/ml - active: midazolam 5 mg/ml (present as midazolam hydrochloride 5.5556mg/ml)   excipient: hydrochloric acid sodium chloride sodium hydroxide as 1n solution, for ph adjustment, ph 3.3±0.1 water for injection - hypnovel is indicated for adults · premedication before induction of anaesthesia · conscious sedation before diagnostic or surgical interventions carried out under local anaesthesia · long-term sedation in intensive care units · induction and maintenance of anaesthesia. as an induction agent in inhalation anaesthesia or a sleep-inducing component in combined anaesthesia, including total intravenous anaesthesia. children · premedication before induction of anaesthesia · conscious sedation before diagnosticc or surgical interventions carried out under local anaesthesia · ataralgesia in combination with ketamine · ataralgesia in combination with ketamine in children (i.m. administration).

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

novel laboratories, inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hydrochloride 5 mg - oxycodone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.   (1) limitations of use (1) because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - have not been tolerated or are not expected to be tolerated, - have not provided adequate analgesia or are not expected to provide adequate analgesia. oxycodone hydrochloride tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.2)] . - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment or hypercarbia [see warnings and precautions (5.6)] . - known or suspected gastrointestinal obstruc

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

novel laboratories, inc. - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - metoclopramide hydrochloride orally disintegrating tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (gerd) who fail to respond to conventional therapy. metoclopramide hydrochloride orally disintegrating tablets are indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (gastric stasis) in adults. metoclopramide hydrochloride orally disintegrating tablets are indicated for adults only. therapy should not exceed 12 weeks in duration. the safety and effectiveness in pediatric patients have not been established. do not use metoclopramide whenever stimulation of gastrointestinal motility may be dangerous such as in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. metoclopramide is contraindicated in patients with pheochromocytoma because the drug may precipitate a hypertensive crisis, most likely due to release of catecholamines from the tumor. such hyperte

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

novel laboratories, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 5 mg - attention deficit disorders, narcolepsy attention deficit disorders  (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfun

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

novel laboratories, inc. - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - dextroamphetamine sulfate 5 mg - dextroamphetamine sulfate tablets usp are indicated for: 1.         narcolepsy. 2.         attention deficit disorder with hyperactivity , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy